3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
144
Radiotherapy
71
Fluorouracil
50
Radiotherapy, Intensity-Modulated
45
Docetaxel
39
Gemcitabine
38
Cetuximab
38
Carboplatin
31
pembrolizumab
25
Capecitabine
22
Drug Therapy
17
toripalimab
14
Paclitaxel
14
camrelizumab
10
Surgical Procedures, Operative
10
Nivolumab
10
Chemoradiotherapy
10
nimotuzumab
9
Radiation
9
Neoadjuvant Therapy
8
Methotrexate
8
Magnetic Resonance Spectroscopy
8
Chemotherapy, Adjuvant
8
nedaplatin
7
Thyrotropin Alfa
7
Platinum
7
tislelizumab
6
spartalizumab
6
Standard of Care
6
Specimen Handling
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
nanocis
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled